Edit

TRICIDA

http://www.tricida.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tab

Last activity: 13.02.2025

Active

Categories: BioTechDevelopmentDrugMedtechProduct

Tricida, Inc., is a privately-held, clinical stage, biopharmaceutical company focused on the discovery and development of non-absorbed therapies. Tricida’s lead investigational drug candidate, TRC101, represents a first-in-class approach to the treatment of metabolic acidosis, a common complication of chronic kidney disease (CKD) that can result in increased mortality, accelerated progression of kidney disease, progressive muscle breakdown and exacerbation of bone disease.

Followers

310

Website visits

14.2K /mo.

Mentions

Location: United States, California, South San Francisco

Employees: 51-200

Total raised: $484.5M

Founded date: 2013

Twitter

Investors 5

Date	Name	Website
-	Avoro Capi...	avorocapit...
-	Hercules C...	htgc.com
-	OrbiMed	orbimed.co...
-	Vivo Capit...	vivocapita...
-	Longitude ...	longitudec...

Funding Rounds 6

Date	Series	Amount	Investors
15.11.2021	-	$42M	-
28.03.2019	-	$200M	Hercules C...
05.03.2018	-	$100M	-
08.11.2017	Series D	$57.5M	-
27.07.2016	Series C	$55M	Longitude ...
04.03.2015	Series B	$30M	-

Mentions in press and media 27

Date	Title	Description
13.02.2025	Helicore Biopharma: $65 Million (Series A) Raised For Glucose-Dependent Insulinotropic Peptide Platform	Helicore Biopharma, a biopharmaceutical company focused on discovering and developing first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions, announced its emergence from stealth mode wi...
24.01.2023	The rise of venture debt: When biotechs should—and shouldn't—use it	Biotechs are operating on razor-thin margins, struggling in a market that just two years ago was flush with cash for big ideas. But now, these same companies are facing more desperate times and seeking out innovative ways to extend their ca...
03.03.2022	Russia's war in Ukraine is now delaying data readouts, as Tricida says its second-chance trial needs more time	A small cap biotech reported Wednesday that the Russian invasion of Ukraine will delay the interim analysis for a large study, suggesting the war could bring new challenges to the industry. Tricida said Wednesday afterno...
16.11.2021	Tricida : Raises $42 Million in Registered Direct Equity Financing - Form 8-K	Tricida Raises $42 Million in Registered Direct Equity Financing SOUTH SAN FRANCISCO, Calif., November 15, 2021 - Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational...
15.11.2021	Tricida Raises $42 Million in Registered Direct Equity Financing	-
15.11.2021	Tricida Raises $42 Million in Registered Direct Equity Financing	SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-...
15.11.2021	Tricida Raises $42 Million in Registered Direct Equity Financing	SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-...
09.11.2021	Tricida Announces Third Quarter 2021 Financial Results	SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-...
15.09.2021	Tricida : Investor Presentation, September 2021	Slowing the Progression of Chronic Kidney Disease Tricida Investor Presentation September 2021 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statement...
09.12.2020	Tricida : End-of-Year Business Update Presentation	Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation - Year-End Business Update December 8, 2020 Forward Looking Statements Any statements contained in this presentation or made during the ...
09.12.2020	TRICIDA, INC. Tricida : End-of-Year Business Update Presentation	Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation - Year-End Business Update December 8, 2020 Forward Looking Statements Any statements contained in this presentation or made during the ...
06.08.2020	TRICIDA, INC. Tricida : Investor Presentation, August 2020	Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation August 2020 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation t...
28.03.2019	Tricida Announces $200 Million Debt Facility With Hercules Capital	-
05.03.2018	Tricida Receives $100M Venture Debt Financing	Tricida, Inc., a South San Francisco, CA-based late-stage pharmaceutical company, entered into a $100m venture debt facility with Hercules Capital, Inc. (NYSE: HTGC). Tricida drew down $25m from the venture debt facility at closing. An addi...
09.11.2017	Term Sheet — Thursday, November 9	CAN TECH STARTUPS SAVE PRINT? Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop This illustrates an interesting trend I’ve noticed recently. While traditional media companies are pivoting to vi...
08.11.2017	Tricida Announces Closing of $57.5M Series D	SOUTH SAN FRANCISCO, CA, Phase 3 stage biopharmaceutical company focused on the discovery and development of non-absorbed oral drug therapies, has closed an oversubscribed $57.5M Series D. >> Click here for more funding data on Tri...
08.11.2017	Tricida Raises $57.5M in Series D Financing	Tricida, Inc., a South San Francisco, CA-based Phase 3 stage biopharmaceutical company focused on the discovery and development of non-absorbed oral drug therapies, closed a $57.5m Series D financing. Wellington Management Company LLP, Venr...
27.07.2016	Tricida raises $55M to prep trials, commercial path for kidney drug	Tricida declined to comment about the funding beyond its news release, which said that the capital will be used to finance late-stage clinical trials of its lead drug candidate, TRC101. Tricida is currently evaluating its compound in 100 pa...
25.07.2016	Longitude Capital Leads $55M Series C for Tricida	SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc., a privately-held, clinical stage, biopharmaceutical company focused on the discovery and development of first-in-class chronic therapies for patients with chronic kidney disease (...
25.07.2016	Tricida Announces $55M Series C Financing	SOUTH SAN FRANCISCO, CA, Privately-held, clinical stage, biopharmaceutical company announced today that it has raised a $55M Series C round. >> Click here for more funding data on Tricida >> To export Tricida funding data to...
25.07.2016	Tricida raises $55M, to get kidney disease data this year	California upstart Tricida has raised its highest level of cash to date with a $55 million Series C funding round backed by major biotech VC players. The South San Francisco company saw its latest round led by new investor Longitude Capital...
25.07.2016	Biopharmaceutical Company Tricida Raises $55M Series C Funding	Tricida, Inc., a South San Francisco, CA-based clinical stage, biopharmaceutical company focused on the discovery and development of chronic therapies for patients with chronic kidney disease (CKD), raised $55M Series C funding round. The r...
06.03.2015	Funding roundup - week ending 3/6/15 Retrieve Voicemail Online or By Phone	Nextdoor, YouMail, RockYou, Tempered Networks, Culture Amp, Vanhawks, Alation, Farfetch, WorldStores Seed stage Smartbike startup Vanhawks raised $1.6 million from Real Ventures, Simon Whitfield, Brenda Irwin and various angels. Product vis...
06.03.2015	Tricida Raises $30 Million In Series B Funding	Tricida is a biopharmaceutical company that focuses on discovering and developing chronic therapies addressing the complications of renal disease. The company has announced that it has raised $30 million in Series B funding. OrbiMed led thi...
04.03.2015	Tricida Closes $30M Series B Financing	Tricida, Inc., a South San Francisco, CA-based biopharmaceutical company focused on the discovery and development of chronic therapies addressing complications of renal disease, closed a $30m Series B financing. The round was led by existin...
04.03.2015	Tricida Announces Closing of $30M Series B	SOUTH SAN FRANCISCO, CA, Privately-held biopharmaceutical company closes $30M Series B financing. >> Click here for more funding data on Tricida >> To export Tricida funding data to PDF and Excel, click here Tricida, Inc....
-	Tricida raises $55M to prep trials, commercial path for kidney drug	Patients who have chronic kidney disease face permanent kidney damage and the prospect of end-stage renal failure. Clinical-stage drug developer Tricida is trying to bring patients who suffer from this condition a new treatment and it now h...

TRICIDA

Investors 5

Funding Rounds 6

Mentions in press and media 27

Reviews 0